Email this article Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison
- Authors: Chowdhury S.1, Oudard S.2, Uemura H.3, Joniau S.4, Dearden L.5, Capone C.6, van Sanden S.6, Diels J.6, Hadaschik B.A.7
-
Affiliations:
- Department of Medical Oncology, Guy’s, King’s, and St. Thomas’ Hospitals
- Georges Pompidou Hospital, University of Paris
- Yokohama City University Medical Center
- University Hospitals Leuven
- Janssen Global Services
- Janssen EMEA
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, University of Duisburg-Essen
- Issue: Vol 18, No 1 (2022)
- Pages: 77-89
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 08.05.2022
- URL: https://oncourology.abvpress.ru/oncur/article/view/1577
- DOI: https://doi.org/10.17650/1726-9776-2022-18-1-77-89
- ID: 1577
Cite item
Full Text
Abstract
.
About the authors
S. Chowdhury
Department of Medical Oncology, Guy’s, King’s, and St. Thomas’ Hospitals
Author for correspondence.
Лондон
United KingdomS. Oudard
Georges Pompidou Hospital, University of Paris
Париж
United KingdomH. Uemura
Yokohama City University Medical Center
Иокогама
JapanS. Joniau
University Hospitals Leuven
Левен
BelgiumL. Dearden
Janssen Global Services
Нью-Джерси
United StatesC. Capone
Janssen EMEA
Бирс
BelgiumS. van Sanden
Janssen EMEA
Бирс
BelgiumJ. Diels
Janssen EMEA
Бирс
BelgiumB. A. Hadaschik
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, University of Duisburg-Essen
Эссен
GermanyReferences
Supplementary files
